<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478060</url>
  </required_header>
  <id_info>
    <org_study_id>CB001</org_study_id>
    <nct_id>NCT02478060</nct_id>
  </id_info>
  <brief_title>Birch-SPIRE Safety and Efficacy Study</brief_title>
  <official_title>A Double-Blind, Randomised, Placebo-Controlled, Escalating, Multiple Dose Study in to Assess the Safety, Tolerability and Pharmacodynamic Effects of Birch-SPIRE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of multiple
      administrations of Birch-SPIRE. To make a preliminary assessment on pharmacodynamic
      parameters and clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Birch-SPIRE administrations measured by Adverse Events</measure>
    <time_frame>Up to 16 weeks after start of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of IgE as a Pharmacodynamic parameter</measure>
    <time_frame>Up to 9 months after start of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Provocation Test as a Pharmacodynamic parameter</measure>
    <time_frame>Up to 9 months after start of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Prick Testing as a Pharmacodynamic parameter</measure>
    <time_frame>Up to 9 months after start of dosing</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Allergy symptoms and allergy medication use during next Birch season</measure>
    <time_frame>Up to 9 months after start of dosing</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Birch-SPIRE or placebo, 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Birch-SPIRE or placebo, 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Birch-SPIRE or placebo, 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Birch-SPIRE or placebo, 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Birch-SPIRE or placebo, 2 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Birch-SPIRE</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 to 65 years;

          -  Minimum 1 year history of rhinitis with or without conjunctivitis on exposure to birch
             pollen

          -  Birch IgE ≥ 0.35 kU/L

          -  Positive skin prick test to whole birch allergen

        Exclusion Criteria:

          -  Any past history of asthma

          -  FEV1 &lt; 80% of predicted

          -  History of severe allergic reaction to birch allergen, severe drug allergy, severe
             angioedema or severe allergic reactions to food

          -  Acute phase skin response to whole birch allergen with a mean wheal diameter &gt; 50mm

          -  Administration of adrenaline (epinephrine) is contraindicated

          -  History of severe drug allergy or anaphylactic reaction to food.

          -  History of any significant disease or disorder (e.g. immune system, pulmonary,
             cardiovascular, gastrointestinal, liver, renal, neurological, metabolic, malignant,
             psychiatric, major physical impairment, history of alcohol or drug abuse)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre de Recherche Appliqué en Allergie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Birch</keyword>
  <keyword>Rhinitis</keyword>
  <keyword>Rhinoconjuntivitis</keyword>
  <keyword>SPIRE</keyword>
  <keyword>Toleromune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

